Atirmociclib作为一种CDK4选择性抑制剂，与现有的CDK4/6抑制剂哌柏西利相比，其在结构上对CDK4的亲和力更高，选择性更强。 细胞 ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer. At the 42nd Annual Miami Breast Cancer Conference, Dr. Sara M. Tolaney sat down for ...

Medscape, December 20, 2024 SABCS 2024 HRQOL the Same With CDK4/6 Inhibitors in 1st or 2nd Line An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 ...